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Abstract 
Purpose: To determine the effect of curcumin (as Meriva) on absolute lymphocyte count (ALC), T 
cell populations and NK cells in patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) 
over a period of six months. Experimental Design: Twenty-one patients with significant lympho-
cytosis (>20 × 109 lymphocytes/L) and stage 0/1 CLL were recruited into the study and received 
oral curcumin 2 grams/day. Blood samples were collected at baseline and at 2 monthly intervals 
for six months for full blood count, leukocyte surface antigens, liver function, serum biochemistry, 
immunoglobulins, CRP and ESR. A positive biologic response was defined as a reduction in the ALC 
of more than 20% from pre-treatment levels. Results: Four patients (20%) demonstrated more 
than 20% decrease in ALC, three of whom had lower ALC at the end of the study as compared to 
baseline. The decrease in ALC was accompanied by an increase in CD4, CD8 and NK cells. No de-
monstrable response was seen in seventeen patients (80%) who exhibited stable, fluctuating or 
increasing ALC during the study. Conclusion: A subgroup of stage 0/1 CLL patients may be respon-
sive to curcumin therapy. The beneficial response appears to be immunomodulated. 
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1. Introduction 
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in the Western world [1]. It in-
volves mature-appearing defective neoplastic lymphocytes (almost always B cells) with an abnormally long life 
span. The peripheral blood, bone marrow, spleen, and lymph nodes undergo leukemic infiltration. Nonspecific 
symptoms include fatigue and malaise and are usually attributable to the anemia. Clinical signs include lympha-
denopathy, splenomegaly and hepatomegaly. Diagnosis is confirmed by examination of peripheral smear and 
bone marrow aspirate. Patients with CLL have been shown to have elevated T cell (CD3, CD4 and CD8) and 
NK cell populations [2]. A higher number of T and NK cells have been associated with delayed disease progres-
sion and time to treatment [3]. 
Unlike most malignant disorders in which early diagnosis increases the probability of a patient cure, treatment 
of unselected early-stage CLL patients with chemotherapy is associated with increased toxicity and no increase 
in survival [4] [5]. There is no published intervention that alters the course of disease for patients with early 
stage CLL i.e. Stage 0 or 1 disease (Rai staging system) [6]. These patients are usually monitored and com-
mence therapeutic intervention if there is disease progression. This approach may often lead to patient’s anxiety. 
These patients represent an excellent cohort to evaluate the efficacy of nutraceutical agents (with a favourable 
toxicity) for disease prevention or delay in disease progression (PD).  
Nutraceutical agents such as epigallocatechin gallate (EGCG) derived from green tea, and curcumin, derived 
from turmeric, have been proposed as health-promoting substances that may reduce cancer risk. Phase 1 and 2 
studies using oral green tea extract (EGCG) [7]-[9] have shown that patients with low grade CLL with/out lym-
phadenopathy demonstrate durable declines in ALC, suggesting an anti-cancer responsiveness.  
Curcumin has been shown to be a potent cytotoxic agent for primary CLL B cells by inhibiting specific pro-
survival pathways such as STAT3, AKT and NF-kB [10]. Moreover, curcumin also suppresses the expression of 
the anti-apoptotic proteins Mcl-1 and X-linked inhibitor of apoptosis protein (XIAP), and up-regulates the 
pro-apoptotic protein BIM. A combination of green tea extract and curcumin selectively upregulates STAT3 
protein and its phosphorylation status when administered in co-culture of CLL B cells with stromal cells, while 
curcumin alone is able to overcome the stromal-induced protection when administered with EGCG in a sequen-
tial fashion [11]. These data suggest a potential therapeutic role for curcumin in the treatment of stage 0/1 CLL.  
We administered curcumin as Meriva, a standardized mixture of natural curcuminoids and lecithin in a 1:2 ra-
tio [12] [13], to 21 individuals with stage 0/1 CLL to determine 1) its effect on ALC, and 2) whether any ob-
served effect could be mediated by the numbers of CD4, CD8 and NK cells. Our previous data has demonstrated 
the safety and efficacy of this compound in MGUS/SMM patients [14]-[17]. Meriva was chosen for this study 
based on its increased absorption and bioavailability.  
2. Materials and Methods  
Twenty-one patients with significant lymphocytosis (>20 × 109 lymphocytes/L) and Rai stage 0 (early CLL and 
lymphocytosis) or stage 1 (CLL and lymphadenopathy) were recruited. Blood was collected at 6 and 3 months 
prior to commencement of therapy, at 2 monthly intervals for a period of six months during therapy and at 3 
months after completion of therapy. Patients were administered oral curcumin (as Meriva) 2 grams/daily in a di-
vided dose. Blood samples were collected for full blood count, leukocyte surface antigens, liver function, serum 
biochemistry, immunoglobulins, CRP and ESR at each visit. A positive biologic response was defined as more 
than 20% reduction in the ALC from the pre-treatment (baseline) levels. 
The protocol was reviewed and approved by the South Eastern Sydney and Illawarra ethics committee. All 
patients provided written informed consent before study enrolment in accordance with the Declaration of Hel-
sinki.  
3. Results 
There were 14 men and 7 women with mean age of 68 (±12.8) years and mean baseline ALC of 30.1 × 109 
cells/L (normal 1.0 - 4.0 × 109/L). Table 1 and Table 2 show the mean baseline clinical and immunological data. 
Twenty-one patients completed 2 months of the study, 3 withdrew at month 2 and a further 2 at month 4. Most 
patients in this study had elevated baseline populations of CD4 (mean 2.2 × 109/L, normal 0.7 - 2.1 × 109/L), 
CD8 (mean 2 × 109/L, normal 0.2 - 0.9 × 109/L) and NK (mean 1.1 × 109/L, normal 0.05 - 0.6 × 109/L) cells and 
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low IgM values (mean 0.3 g/L, normal 0.48 - 3.04 g/L).  
There were four patients (20%) who demonstrated a positive biologic response i.e. >20% reduction in ALC 
during the course of the study (Table 3). Their pre-study, during study and post-study ALC values are shown in 
Table 3. Three of the four had a lower ALC at the end of the 6 month study period. All four patients showed a 
relapse and an increase in ALC at three months post-study drug withdrawal. The decrease in ALC was accom-
panied by an increase in the CD4 count in all 4 patients (100%) after 2 months of curcumin therapy, and an in-
crease in CD8 and NK cells in 2 (50%) patients after 2 months of curcumin therapy. The elevated CD4, CD8 
and NK cell counts returned to baseline values at 6 months in all patients. The mean CD4, CD8 and NK cell 
populations at baseline and during the study are shown in Table 4. 
Seventeen patients (80%) failed to show a positive response to curcumin therapy. They showed stable, fluctu-
ating or increases in ALC during the course of the study (Table 5). The pre-study, during study and post-study 
ALC values of these patients are shown in Table 5. Among the non-responders, 6 (35%) showed an increase in 
CD4 count after 2 months of curcumin therapy, 4 (23%) showed an increase in CD8 count and 4 (23%) showed 
an increase in NK cell count after 2 months of curcumin therapy.  
 
Table 1. Mean baseline clinical and haematological data in all patients. 
 Age WCC (4 - 11 × 109/L) 
ALC 
(1 - 4 × 109/L) 
Hb 
(130 - 180 g/L) 
Pltlts 
(150 - 450 × 
109/L) 
LDH 
(120 - 250 U/L) 
ALT 
(5 - 40 U/L) 
Hct 
(0.39 - 0.54) 
Mean ± SD 68 ± 12.8 35.0 ± 9.9 30.1 ± 10.1 142.3 ± 12.7 185.9 ± 49.7 196.7 ± 34.2 27.1 ± 14.9 0.43 ± 0.03 
 
Table 2. Mean baseline immunological data in all patients. 
 
IgG  
(6.2 - 
14.4 g/L) 
IgA 
(0.6 - 
3.96 g/L) 
IgM 
(0.48 - 3 
g/L) 
CD3 
(0.7 - 2.1  
× 109/L) 
%CD3 
CD4 
(0.4 - 1.4  
× 109/L) 
%CD4 
CD8 
(0.2 - 0.9  
× 109/L) 
%CD8 CD 4/8 (1 - 3) 
NK 
(0.05 - 0.6 
× 109/L) 
% NK 
CD19 
(0.05 - 0.5 
× 109/L) 
%CD19 
Mean ± 
SD 
8.8 ±  
2.8 
1.3 ±  
0.9 
0.3 ±  
0.2 
4.7 ±  
2.3 
17 ±  
9.3 
2.3 ±  
1.2 
8.2 ±  
4.5 
2 ±  
1.4 
7 ±  
5.2 
1.5 ±  
0.7 
1.1 ±  
0.7 
3.9 ±  
2.6 
24.5 ±  
10.1 
79.7 ± 
9.9 
 
Table 3. ALC counts of responding patients at 6 months and 3 months pre-study, during study and 3 months post-study. 
Patient No. −6 (n = 4) 
−3 
(n = 4) 
0 
(n = 4) 
2 
(n = 4) 
4 
(n = 3) 
6 
(n = 3) 
+3 
(n = 3) 
1 24.9 22.8 26 18.2   20.2 
4 32 34.4 43.9 42.3 34.3 41.3 44.3 
9 48.5 43.9 49.9 30.2 31.1 36.7 43.2 
11 18.3 29.5 38.3 38.7 24.7 40.6  
Mean ± SD 30.9 ± 12.9 32.7 ± 8.9 39.5 ± 10.2 32.3 ± 10.7 30 ± 4.9 39.5 ± 2.5 35.9 ± 13.6 
 
Table 4. CD4, CD8 and NK cell counts (Mean ± SD) in responding and non-responding patients. 
 Baseline 2 months p-value 4 months p-value 6 months p-value 
CD4 resp. 1.38 ± 0.5 (n = 4) 2.93 ± 1.6 (n = 4) 0.1 1.11 ± 0.4 (n = 3) 0.1 1.2 ± 0.3 (n = 3) 0.1 
CD4 non-resp. 2.43 ± 0.9 (n = 17) 2.37 ± 0.9 (n = 17) 0.8 2.07 ± 0.8 (n = 15) 0.2 2.17 ± 0.8 (n = 13) 0.2 
CD8 resp. 2 ± 1.5 (n = 4) 2.68 ± 1.9 (n = 4) 0.3 1.8 ± 1.2 (n = 3) 0.3 1.4 ± 0.3 (n = 3) 0.3 
CD8 non-resp. 2.03 ± 1.4 (n = 17) 1.61 ± 0.9 (n = 17) 0.1 1.63 ± 0.9 (n = 15) 0.9 1.5 ± 0.7 (n = 13) 0.3 
NK resp. 1.11 ± 0.3 (n = 4) 1.46 ± 0.7 (n = 4) 0.3 0.69 ± 0.5 (n = 3) 0.3 0.83 ± 0.3 (n = 3) 0.3 
NK non-resp. 1.06 ± 0.8 (n = 17) 1.09 ± 0.7 (n = 17) 0.9 1 ± 0.6 (n = 15) 0.3 1.2 ± 0.9 (n = 13) 0.3 
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Table 5. ALC counts of non-responding patients at 6 months and 3 months pre-study, during study and 3 months post- 
study. 
Patient No. −6 (n = 17) 
−3 
(n = 17) 
0 
(n = 17) 
2 
(n = 17) 
4 
(n = 15) 
6 
(n = 13) 
+3 
(n = 15) 
2 34.3 31.1 30.7 40.2 30.6 51.5 30 
3 50.9 47.4 44.1 45.8 49.3 55.7 63.6 
5 23.3 25.4 25.9 25.3 23.4 27.0 32.3 
6 32.9 37.2 23.9 24.1 28.4 23.3 33.4 
7 13.8 18.3 14.6 17.9   12.8 
8 30.2 37.9 33.9 30.4 36.2  36.5 
10 17.8 17.2 21.7 18.6 19   
12 43.9 43.9 38.3 40    
13 20.7 23.2 20.2 23.2 19.8 27.4 25.8 
14 21.5 25.7 18.9 29.9 26.7 24.5 27.9 
15 21.8 17.4 23.8 23.7 28.2 29.7 37.9 
16 16.1 22.9 25.3 30.6 35 38 36.5 
17 20.4 25.7 29.3 25.9 24.2 39.3 47.7 
18 41.2 32 44.8 45.2 56.5 54 54.7 
19 41.2 45.5 35.8 40.3 35.9 35.8 51.8 
20 17.6 20.8 18.9 21 19.5 19.3 20.2 
21 20.9 18.7 23.1 19.9 23.7 23.9 24.9 
Mean ± SD 27.6 ± 11.2 28.8 ± 10.2 27.8 ± 8.9 29.5 ± 9.4 30.4 ± 10.8 34.6 ± 12.4 35.7 ± 13.7 
 
Responding patients (i.e. >20% decrease in ALC) show a greater increase in T cell and NK cell response (in-
crease in CD4, CD8 and NK cells with R = 0.81, 0.8 and 0.7 respectively) as compared to the non-responders (R 
= 0.09, 0.05 and −0.2 respectively).  
4. Discussion  
Our study results suggest that curcumin may be beneficial in a small subset of early CLL patients due to its 
anti-tumour activity. The decrease in ALC count seen in 4 (20%) of these patients corresponded with an increase 
in CD4 T cells, a similar finding to Varalakshami [18] in their mouse model. An increase in CD8 T cell and NK 
cells was also seen in 2 of the responders and 4 of the non-responders, perhaps due to curcumin therapy. Immu-
nomulation of CD4 T cell, CD8 T cell and NK cell subsets has been found in numerous studies on curcumin 
therapy [18]-[21].  
There is a marked clinical heterogeneity in patients with CLL that is associated with a heterogeneous array of 
genetic and molecular defects [3]. The complexity of this malignancy is further increased by the interaction of 
leukaemia cells with the microenvironment. Leukaemia cells closely interact with accessory and immune cells 
that regulate their trafficking, survival and proliferation. Patients with leukemia have been shown to have ele-
vated T and NK cell populations and the relative numbers of T and NK cells at diagnosis has been associated 
with clinical outcome. A study by Huergo-Zapigo [3] has shown that CLL patients with a relative CD8 count > 
0.03 showed significantly longer time to treatment than those with lower numbers of CD8 T cells, suggesting 
that CD8 may modify disease progression. This suggests that the non malignant immune system may play an 
important role in the pathogenesis and progression of this malignancy and that the expansion of T cells observed 
in patients with CLL may be due, in part, to the expansion of anti-tumor T cells [2]. A possible role for curcu-
T. Golombick et al. 
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min therapy may be further expansion of these anti-tumor T cells. Our results suggests that a decrease in the ab-
solute lymphocyte count of responding patients may be due to an augmentation of the T cell response.  
The expected pattern for the majority of patients with early CLL is a rising ALC and progressive lymphade-
nopathy. Fluctuations in ALC can be expected in a subset of patients with CLL. Our data supports these findings 
as shown by the ALC fluctuations seen in the non-responding patients (80%).  
Limitations of this study include the small number of patients and the number of patients who dropped out of 
the study. Among the 5 patients that did not complete the 6 month study, 2 withdrew due to gastro-intestinal 
disturbance caused by the curcumin. No other toxicity was noted in the remaining patients.  
Curcumin has a high hydrolytic instability at physiological pH and an inherently low intestinal absorption. It 
is therefore poorly bioavailable, with only conjugates being generally detectable in plasma even after dosages as 
high as 12 g/day. Curcumin is sparingly soluble in both water and lipophilic organic solvents, but has polar 
groups that make it a good candidate for phospholipid complexation. A novel curcumin formulation was devel-
oped under the brand name Meriva by combining a standardized mixture of natural curcuminoids and lecithin in 
1:2 ratio, with 2 parts of microcrystalline cellulose being added to improve the physical state. The relative ab-
sorption of a standardized curcuminoid mixture and its corresponding lecithin formulation (Meriva) was inves-
tigated in a randomized, double-blind, cross-over human study and total curcuminoid absorption was about 
29-fold higher for Meriva than for its corresponding unformulated curcuminoid-like mixture [12] [13]. Thus 
Meriva was chosen for this study solving the issue of megadoses even though curcumin had been found to be 
safe even at doses as high as 12 g/day. There is safety data with a number of patients treated with curcumin for 
as long as 10 years at a dose of 6 g/day (Golombick et al. Unpublished Data). 
Although current prognostic indicators [ZAP-70, CD38, IGHV mutation status, fluorescence in situ hybridiza-
tion (FISH)] are able to identify early stage CLL patients at high risk of rapid disease progression, these tests are 
not routinely performed in our laboratory and were not performed as part of their work-up.  
5. Conclusion 
In conclusion, the results of this 6-month study suggest that a small percentage of early CLL patients may derive 
benefit from curcumin therapy by decreasing their ALC, perhaps through stimulating an immune response by 
increasing CD4, CD8 and NK cells. CD8 cytotoxic T lymphocytes are involved in antigen-specific tumor de-
struction and CD4 T cells are essential for helping the CD8 T cell-dependent tumor eradication. A number of 
nutraceutical agents have been shown to have an immunostimulatory effect and combining their action with 
curcumin may be synergistic. The analysis of the number of different subsets of T cells should be taken with 
caution since the functionality of these subsets may be diverse. Follow-up activation studies are suggested. Our 
results suggest that a larger study is warranted. 
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